Stats

A news scan found the headline that a new Oracle filing strengthens the financing bear case, and the Copart tender still lacks a fixed expiry. Today, the September 11 Oracle 10Q filing was made available at https://www.sec.gov/Archives/edgar/data/1341439/000119312526389274/orcl-20260831.htm, which can be accessed via EDGAR CLI, showing the first 60,000 characters. The filing includes the following information: (1) the operating cash flow for the first quarter of 2023 was $23.103 billion, which includes $11.363 billion in financing prepayments, and capital expenditures were $28.499 billion, resulting in a free cash flow of -$5.396 billion. (2) The net ATM equity issuance was $19.909 billion, which funds the buildout, and excluding financing prepayments, the free cash flow was -$16.759 billion, which is an analytical bridge, not GAAP. (3) An additional $288 billion in leases is expected to commence between fiscal year 2027 Q2 and fiscal year 2029 for 15-19 years, but this is not a recognized liability. The remaining performance obligations of $664 billion with 13% equals $86.32 billion in expected revenue within 12 months, which is not cash or profit and cannot offset leases dollar for dollar. The strongest bear case is that long fixed capacity commitments plus dilution require utilization and margins to catch up. On the other hand, customer prepayments and a large contract backlog share funding risk and could produce high future cash. There are three orders: buildout funding, equipment and power payments, and future lease obligations, which depend on profitable usage with less flexibility. There is no new run update and no order. The Copart filing on September 11, https://www.sec.gov/Archives/edgar/data/900075/000119312526388383/d138398dsctoc.htm, is a preliminary tender communication, not a commencement or expiry. The planned ACV deal requires two regulator and integration and cash commitments, and returns on capital must beat the cash alternative, but counter dealer wholesale platform synergies. There is no fixed arbitrage date from the SC TO-C. The latest two filings from ADBE on September 10 and September 8 did not return any new information on September 11, and prior cash analysis was reused, with no organic growth bridge verified. The full CPRT exhibit transcript and Oracle later 10Q sections are explicit gaps, not presumed unchanged.

The automated trading fund manager has reviewed the calendar for potential trading opportunities. The manager looked at various companies, including those in the US retail, publishing, restaurants, and software industries, as well as overseas companies like NEXT and Egetis. The manager also considered FDA panels and macroeconomic factors, but this is not an exhaustive list of all global companies. The manager verified dates between observations 25297 and 25304. For example, Nike is expected to release earnings on October 1 at approximately 16:15 ET, with a default exit date of September 30. The manager also noted that NXT.L has a date of September 17, and EGTX.ST has a date of September 28 for a PDUFA, which is a US Food and Drug Administration decision, with cash of 378 MSEK as of June 30, including 350 MSEK in gross financing from April. However, the manager found conflicting information for FDX, with an external estimate of September 17 that conflicts with the unhelpful issuer homepage, and no primary confirmation or actionable date. The manager also reviewed the Federal Register, which sets an October 1 meeting for strain selection, but this is not a company payoff, so the manager rejected this entry. The manager verified US companies HAIN, HITI, and PLAY on Monday, September 14, but the default last session exit of September 11 has passed. Prior attempts to buy HITI, HAIN, and PLAY had failed or were uncertain, and the manager will not make a late buy. The manager used various sources, including investor websites and news articles, to gather information. The manager also noted that crypto macro dates alone do not provide enough information to identify a trading opportunity, and no token event or tradable price edge has been established. The manager concluded that calendar verification is necessary but not enough, and eligibility, foreign exchange, and payoff are uncertain for foreign companies. The manager also noted that passed windows cannot be moved. As a result, the manager decided to allocate zero funds and preserve outcome monitors and collectors. No separate book is proposed because there is no independently demonstrated outside-mandate operation.

A diagnostic test was run using a command line interface to evaluate a momentum-based trading strategy on the stock SCHL. The test, which used 752 bars of data and resulted in 50 trades, showed a return of -20.343012% and a maximum drawdown of 46.486672%. The test also showed that the strategy was only successful 30% of the time, with a mean trade return of -0.284097%. For comparison, a buy and hold approach would have resulted in a return of -16.387760%. The data used for the test came from https://runway.adityaperswal.workers.dev/data/stock-bars. This test was a basic diagnostic and did not take into account factors such as fees and slippage, and the results cannot be used to authorize the use of capital. A separate study, known as event study 2768, used more detailed data and a longer time period, and also showed negative results for the momentum-based strategy. The test was run on September 24 and the results confirm that the momentum-based strategy is not valid. The conclusion is that there is no basis for using a momentum-based entry strategy, and no parameters were found that could improve the results.

A news scan found the text: Numpyseed91200; 100,000 independent and identically distributed paths of 10 trades were resampled from 16 SCHL training event returns of the preregistered T5/1ADRstop/3ADRtarget daily proxy. The same underlying 22 issuer date cohort and explicit IEX source https://runway.adityaperswal.workers.dev/data/stock-bars?feed=iex&adjustment=all were used. The quarter fund deployment mean terminal was -0.258428%, the loss frequency was 55.485%, and the 5th and 95th percentiles were -4.54516% and +4.46660% respectively. The 95th percentile drawdown was 5.10136%. The full fund mean was -1.14268%, the loss frequency was 57.209%, and the 5th and 95th percentiles were -17.35808% and +18.26072% respectively. The 95th percentile drawdown was 19.18431%. These are model frequencies conditional on 16 events, not estimates from 100,000 independent observations, and omit unseen FDA gaps or regime changes. The premises are: historical training edge is negative; repeated trades compound that loss; sizing only changes amplitude. The conclusion is allocation 0, training half Kelly 0; it is not possible to manufacture positive expectancy by quarter probe. A strong countercase is that an unseen new regime could improve payoff, but it needs prospective evidence, not a shortfall of 349.01. The hard limit is a fund of 49.14; an assumed 50% whole fund gap costs 24.57, which is 2.88723% of the account, and the total loss is 5.77445%. These deterministic stress losses carry no assigned odds. There is no traded simulation and no live stop.

A trading fund manager's notes were frozen before new returns were added. The notes cover the period from T-5 open to T-1 close, with a stop loss set at 1 times the prior 20-day average daily range and a target set at 3 times the average daily range. The manager used a static daily proxy and verified 22 issuer release dates from the Scholastic investor website. The manager trained the model from 2021 to 2024 and used data from 2025 to July 2026 as a known holdout. The manager used adjusted data from the IEX exchange, which is a stock exchange that provides real-time data, and a Python custom script to fill orders with targets capped. The manager also used a vectorbt long-only strategy, which is a type of trading strategy that only buys stocks, with fees of 5 basis points and a slip of 10 basis points on each side. The initial cash was set at 100. The manager reconciled the count and compounded returns exactly. The training return was -2.64033%, with a drawdown of 12.96266% and a win rate of 37.5%. The mean return was -0.107976% and the W ratio was 4.11688%. The L ratio was 2.64289% and there were 5 targets. In the known holdout period, the return was +2.15046%, with a drawdown of 7.22507% and a win rate of 66.667%. The mean return was +0.407757% and the W ratio was 2.16255%. The L ratio was 3.10184% and there were zero targets. A bootstrap analysis with 20,000 iterations and a 95% confidence interval showed a mean return range of -2.03654% to 3.12124%. A stress test with a 25 basis point slip showed a training return of -7.20323% and a holdout return of +0.328197%. The manager concluded that the gross 3R geometry was less than the net 3R and that empirical wins were time exits, not demonstrated tail capture. The Half Kelly capital formula, which is a formula used to determine the optimal amount of capital to allocate to a trading strategy, yielded 0 in training and was mechanically capped at 1 in the selected known holdout, but was found to be unstable and not adopted. The manager noted that prior research had seen the same holdout results and that this was a changed exit robustness experiment, not a fresh independent out-of-sample test. The manager also noted that historical date announcement availability and early news and corporate action execution remained gaps. The conclusion was no entry and to preserve the September 17 paper window, not to enter on Monday earlier. The scripts and research are saved in the file test_schl.py and the trade outcomes are saved in the file manifest observations and trade outcomes 25287.

A news scan found the headline that a simplistic bearish trade was contradicted by the SEP1200 tape, with no live stops to reset. On September 11, the daily prices for SCHL were 34.975, which is below the Simple Moving Average of 20 days at 38.65 and the Simple Moving Average of 50 days at 41.671. The Relative Strength Index, a measure of stock price momentum, was 25.867. The 20-session return was -15.376%, and the Average Daily Range for 20 days was 0.89175. A hypothetical stop at 34.08325 and a target at 37.65025 would have a gross return of 3R, but less than 3R after costs. This is a diagnostic price geometry, not a justified order. HOFT was at 12.525, with a 20-day return of -15.600%, and the first IEX open was +7.239% but the close was -0.358%, which supports skepticism about the headline profit. The sparse IEX volume of 1952.5 per day cannot certify liquidity. KR closed at 58.46, +2.6334% despite a guidance cut, so the bearish sales headline alone missed the cash resilience. SRRK had a daily close of 55.39 before approval at 22:25 UTC, with no measured post-approval reaction. SPY was at 764.14, +0.8273% despite a weaker consumer context, with no causal attribution. The premises are: 1) event and timestamp alignment matters; 2) oversold inside a falling trend is not reversal-proof; and 3) stop and target geometry is not expected payoff. The conclusion is to remain flat pending independent window validation, with no existing stops to tighten. A strong countercase of an oversold rally is possible, tested without changing the entry window. The equity and stale price of 49.14 afford one SCHL share, which is approximately 71.17% of the fund, with no SRRK whole share, and no fractional overnight risk is assumed safe.

The fund started with $49.14 in cash and no active trades or pending orders. A review of past trades from the Catalyst fund showed a loss of $31.93, with a win rate of 0% and a mean return of -16.38%. The RARE trade lost 45.86% of its value, which is 6.44 times the intended stop risk. The IONS and MIRM trades were closed by the operator, so their returns do not reflect the natural outcome of the strategy. The planned target-to-risk ratios for these trades were 1.72, 1.40, and 1.08, respectively, all of which are below the current 3R mandate. Based on these results, it was concluded that there is no positive return from this record, and the allocation was set to 0 until a new valid setup is found. This does not mean that every FDA run-up has negative expectancy, as early approvals can produce upside, such as the recent SRRK announcement. The historical trades were fractional, limiting the ability to exit during off-hours. The entry quotes and timestamps are not available, so it is not possible to determine if there was slippage in stop loss execution. The current total loss for the fund would be 5.77% of the account, and a hypothetical 50% gap would result in a loss of 2.89%, regardless of monthly revenue needs.

The demand for SEP1200 has a bear case due to weaker surveys. There are four premises for this case: (1) on September 11, the Bureau of Labor Statistics reported that the August Consumer Price Index increased by 0.4% from the previous month, with the core index increasing by 0.3%, and the core index slowing to 2.4% over the past year. (2) Real hourly pay decreased by 0.1% from the previous month, but longer working hours led to a 0.2% increase in real weekly pay. (3) The University of Michigan's preliminary sentiment index was 47.8, down from 51.7, and one-year inflation expectations were 4.6%, up from 4.0%. (4) The Census reported that applications fell by 7.8% to 531,728, and projected formations for the next four quarters fell by 4.6% to 28,501. These releases do not provide an edge for a company's stock to increase. The strongest argument against this bear case is that Kroger kept its earnings per share guidance of $5.10-$5.30 and free cash flow guidance of $2.7-$2.9 billion, despite cutting its sales midpoint by 1 percentage point. A news scan found the sources of this information to be the Bureau of Labor Statistics and the University of Michigan, among others.

There are no open theses or lots in the venue ledger and no invented stop resets. For SRRK, a 1:1 approval permits treatment and launch, with payer coverage, infusion capacity, and safety determining paid starts. Recurring cash versus launch spend determines dilution and valuation, while background SMN2 therapy providers may benefit from complementary use. However, bear access frictions and fractures, and counter broad label and PRV. For TLX, a September 11 decision could approve or reject, with launch cash or additional CMC and clinical spend to follow. Other pipeline funding and radiopharmacy utilization amplify equity impact. It is not accurate to claim that FDA silence proves delay. For HOFT, refunds boost liquidity, but finite recoveries fade while backlog must become profitable shipments. Enduring weak demand could force cash conservation and less capital returns, but cost cuts and no bank debt improve survival. For KR, sales growth guide falls 1 percentage point midpoint, with mix, price investment, labor productivity, and pharmacy headwinds interacting. Unchanged free cash flow and earnings per share depend on margins, with buybacks reducing float but consuming cash. However, profit guidance is unchanged, and sales cut is not a full volume proxy. For SCHL, sale leaseback converts assets to cash, but leases become future operating obligations. Recurring cash and book value must cover rent, content investment, and capital returns. However, a 35-40 million FY27 free cash flow forecast and lower float may reward owners. These are conditional chains, not assigned probabilities. Sources include SRRK original in 25168, and news releases from Telix Pharma, Hooker Furnishings, Kroger, and Scholastic.

No holdings are currently owned, so the following are watchlist challenges, not exit instructions. The primary source for SRRK is a news release from Scholar Rock, which can be found at https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-fda-approval-isembyldtm-apitegromab-mstn, published on September 11 at 18:25 EDT. This release reports that ISEMBYLD has received FDA approval, 19 days before the goal of September 30. The premises for this approval are: 1) the regulatory risk for this US indication is resolved; 2) eligible patients must already receive SMN2-targeted therapy and shipping and payer access are prospective; and 3) the voucher award is not a cash sale. A bear case for this stock is that launch conversion, fractures, infusion logistics, and manufacturing constraints may limit cash flow, and the approval has already been announced, so it is not possible to buy the stock in anticipation of a run-up on September 30. On the other hand, a countercase is that the broad age label of greater than or equal to 2, the fact that it is the first muscle-targeted treatment, and the voucher can support repricing, but no independent net post-approval strategy has been established. For HOFT, the original source is a news release from Hooker Furnishings, found at https://investors.hookerfurnishings.com/news-releases/news-release-details/hooker-furnishings-reports-profitable-quarter-and-first-half, published on September 11. This release reports: 1) Q2 operating income of $1.3 million, which contains a net operating tariff benefit of approximately $3.8 million; 2) simple normalized operating income is approximately -$2.5 million; and 3) revenue decreased by 8.7% and no additional material tariff recoveries are expected. A bear case for this stock is that the headline profits overstate recurring demand and the cash release cannot recur. On the other hand, a countercase is that the company has $18.7 million in cash and no bank debt, backlog increased by 6.2% year-over-year, and lasting annual cost cuts of $17.5 million may support recovery. The company's free cash flow for the first half of the year was $24 million, minus a $1.1 million refund, which equals $22.9 million, and subtracting a $7.9 million refund results in $15 million before other working capital, which is not perpetual cash. A valid conclusion is to reject automatic entries, as financial soundness is limited by rounded accounting bridges and issuer bias, and no market valuation model has been established yet.

A scheduled repair for PRE91108 has been verified. The final list of jobs showed that 223 out of 224 executions were completed at 08:15:37 UTC, with a successful exit and final completion. This confirmation replaces the pending server verification from 2734, and the local success was also confirmed by the actual venue output. All five original source-collection workflows are still active, with identifiers 126, 132, 172, 223, and 224, and no trading instructions were given. A compact preview provides visibility into completion and errors, but does not retain full documents or economic data. The next runs are scheduled for 10:15 UTC for 223 and 16:15 UTC for 224, and the next manager run is at 12:30 UTC. The source of this information is the list_jobs function for the catalyst fund, which recorded actual receipt observations during this run.

The fund started with $49.14 in cash and $850.99 in the account, with no holdings or pending orders. The goal is to make a profit before the first news event, with the constraint that the payoff must be eligible and executable, and not result in a monthly shortfall of $349.01. The premises for this decision are: 1) recent FDA and call events make it difficult to enter the market in the usual way; 2) studies of past events have not provided conclusive results; 3) the stress on the market's range is negative after accounting for costs; and 4) recent primary results have changed the market's context, but are not a reason to enter the market now. The conclusion is to preserve the $49.14 in cash and not place any orders. This decision is based on unmet timing and payoff requirements, and is limited to the reviewed candidates and studies. The strongest argument against this decision is the positive trend of HITI and potential cash-driven reratings, but this is not enough to justify buying outside the tested window. The allocation is set to 0, and a new measured edge with a verified date would change this decision. Monitors and jobs will preserve follow-up. The sources for this decision include issuer dates, stock bar data, and press releases from Oracle and SEC filings.

A news scan found the following text: 1. list_jobs and saved notes confirm that 126, 132, and 172 have final END markers. Old 205 and 209 exit0 outputs truncate before completion, so exit code alone is insufficient. 2. Preserved original source scripts, wrapped every print in bounded panel receipts with length, hash, and preview error summaries, which is a way to track and verify the output. Local plain and final losslessly packed variants executed successfully: 7 print panels for 205, 11 for 209; both actual END observed, output less than 2200 characters. 3. Initial scheduling failed due to a 4000-character schema, which is a set of rules for organizing data; compressed 2845 and 3049 character variants preserve identical decoded logic. Originals cancelled, replacements submitted on same 120 and 480 minute cadence and 45 and 62 remaining runs. Full raw content exists only inside each sandbox; saved receipts deliberately use previews and never substitute for reading originals. Conclusion: collection completion is auditable; server first-run output remains to be checked at next run. Preserve source and branch manifests in list_jobs cancelled 205 and 209 and note 2305; no sixth collector, no economic conclusion from hashes. Sources include: list_jobs, query_research, and scripts pre91108/collector205.sh and collector209.sh.

The fund starts with $49.14 in cash and no holdings or orders. On Friday, September 11, there are calls for KR and HOFT, but the exact time of the first news is not given. There is also a PDUFA date for TLX Pixclara, which may bring early news. On this day, there will be releases of CPI and real earnings at 8:30 ET, Michigan preliminary sentiment and Census formations at 10:00 ET, and the Fed Z1 at noon ET. On Monday, September 14, HAIN will report before the open and HITI and PLAY will report after the close. The default exit for prior-session positions is set for today. There is an issuer date for Smaregi4431 on September 14, but the hour, venue, and FX are not verified. The BLS and Census calendars show no entries for Monday, but the Fed has routine releases at 13:00 ET, 16:15 ET, and other times, so it is not possible to rule out macroeconomic news. The FDA general calendar is not available, so it is not possible to confirm exhaustive coverage. The existing broad census 2412 is being reused as context, not as a new full-market screen. Strong cash and clinical evidence can change research priorities, but weak or missing releases will retain cash or date uncertainty. Neither outcome can bypass the need for an independent net edge and pre-event exit. Crypto macro exposure alone is not enough to meet the mandate of a dated-company run-up. The sources used are listed, including the BLS, University of Michigan, Census, and Federal Reserve websites, as well as issuer URLs. No orders or stops are required while the fund is flat. The next manager update will be at 12:30 UTC.

A news scan found the following information about the consequences of certain events. Facts are recorded from 2712 to 2715 and 25034 with original URLs. There are three-step conditional chains for several companies. For Oracle, the chain is: (1) Oracle prepayments finance capacity, which means Oracle pays in advance to increase its ability to do things; (2) delivery consumes equipment and power and creates service obligations, meaning that when Oracle delivers something, it uses up equipment and power and has to provide services; (3) shareholder returns depend on utilization and margins after financing, while hardware and power suppliers may receive cash earlier, which means that the amount of money shareholders get back depends on how well Oracle uses its resources and how much money it makes, and the companies that supply Oracle with hardware and power might get paid sooner. A counterargument is that contracted customer funding can reduce equity dilution, which means that when customers pay in advance, it can help Oracle keep more of its own money. For Adobe, the chain is: (1) AI adoption attracts users, meaning that when Adobe uses artificial intelligence, it gets more users; (2) paid conversion and inference costs determine margin, which means that the cost of converting users to paid users and the cost of using artificial intelligence affect how much money Adobe makes; (3) durable cash can fund buybacks, but free users alone cannot, meaning that Adobe can use its steady cash flow to buy back its own shares, but having only free users is not enough to do this. For Copart, the chain is: (1) ACV purchase uses cash, meaning that when Copart buys something, it uses up cash; (2) integration and HSR, which stands for Hart-Scott-Rodino, affect timing and synergies, meaning that when Copart combines with another company and follows antitrust laws, it affects when things happen and how well the companies work together; (3) per-share value depends on returns above alternative cash deployment, which means that the value of each share depends on how much money Copart makes compared to what it could have made if it had used its cash differently. For Zumiez, the chain is: (1) soft traffic pressures sales, meaning that when fewer people visit Zumiez's stores, it affects sales; (2) fixed leases and buybacks consume liquidity, meaning that the cost of renting stores and buying back shares uses up cash; (3) weak holiday cash could reduce future capital returns, meaning that if Zumiez does not make enough money during holidays, it might not have enough money to invest in the future. For TLX, the chain is: (1) approval or CRL, which stands for Complete Response Letter, changes access, meaning that whether or not TLX is approved affects who can use it; (2) launch cash or continued costs follow, meaning that if TLX is launched, it will either make money or continue to cost money; (3) funding and other pipeline valuations amplify equity gaps, meaning that how much money TLX has and how its other projects are valued affect the difference between what investors think it is worth and what it is actually worth. These are just possible scenarios and not predictions or recommendations to trade. Investors should reconsider only with new primary cash evidence and an independent executable event edge. Sources include https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf, https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf, https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322dex991.htm, https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm, and https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/.

A review of the PRE91108 frozen backtest audit was conducted, reusing existing results without running new independent tests. The review examined the original data, which consisted of 244,382,848 entries, without re-running the tests or selecting a new pooled sample or holdout. The results for HITI showed a fixed T-3/T-1 vectorbt with training from 2022 to 2023, resulting in a return of 31.7294% for 8 periods, and a holdout from 2024 to June 26 with a return of 3.75545% for 11 periods, a drawdown of 8.65185%, and a win rate of 63.6364%. The stress test result was 0.38739%, with a mean confidence interval of -0.73259% to 1.53296%. For HAIN, the results showed a T-10/T-1 with training for 13 periods, resulting in a return of 39.3858%, and a holdout for 6 periods with a return of -54.89695%, a drawdown of 56.6170%, and a win rate of 16.6667%. For PLAY, the results showed a T-4/ATR exit with training for 16 periods, resulting in a return of -13.155%, and a holdout for 6 periods with a return of 6.87897%, a drawdown of 12.73711%, and a win rate of 66.6667%, with a mean confidence interval of -4.485% to 7.251%. The prior CLI controls, which consisted of 280, 393, and 848 entries, were also reviewed, and it was noted that generic momentum is not a valid event validation. All studies included assumed fees and slippage, as well as chronological splits, and the reviewed holdouts are now known, rather than being untouched forward evidence. The conclusion of the review was to preserve the rejected or inconclusive rules. All tested entry windows passed before the final pre-event session, and a new intraday purchase would require a new independent test. The sources used for the review included https://runway.adityaperswal.workers.dev/data/stock-bars, https://ir.hain.com/financial-information/quarterly-results, https://hightideinc.com/high-tide-to-announce-third-fiscal-quarter-2026-financial-results/, and https://daveandbusters.gcs-web.com/news-releases/news-release-details/dave-busters-entertainment-inc-report-second-quarter-2026.

The automated trading fund manager performed a live ledger audit on the Catalyst fund. The audit found that the fund has three closed trades and no current holdings or orders. The previous ledger, numbered 2679, still shows a profit and loss of -31.937258, with no winning trades out of three, and an undefined average winning return. Two trades were stopped early by the operator, which affected the intended holding periods. One trade, RARE, entered at 25.84, stopped at 24, and exited at 13.98976, resulted in a loss of 6.44035. This shows that a stop does not guarantee a limit on losses. The audit also found that it is impossible to estimate the probability of winning trades for the new Catalyst fund due to the lack of winning trades. The current feasibility of the fund is 49.14, with an account balance of 850.99, and a 50% fund position gap of 2.8872% of the account. The audit notes that the losses may be understated due to censored data, but this does not validate the performance of an untested final-session entry. The source of the data is a query of trades for the Catalyst fund, using prior measured figures from ledger 2679, which is not a new sample.

A one-session range stress test for PRE91108 showed negative results and was unable to price FDA tails. The test involved analyzing daily high, low, and close ratios for 71 names, translating them to a September 10 reference price. A diagnostic test with a 1ADR stop and 3ADR target was used, with a 30 basis point assumption on each side. The mean net results were -0.7844% for HITI, -0.9210% for HAIN, -0.9050% for PLAY, and -0.6544% for TLX, with target frequencies of 0/0/1.378/0%. This was an unconditional range analysis, not a catalyst backtest or executable model. Entry and overnight gaps were omitted, so the TLX result cannot estimate FDA loss odds. A separate test assumed a 50% gap on a full $49.14, resulting in a cost of $24.57, or 2.8872% of account equity, with a full loss of 5.7745%. The conclusion is that the model does not support inventing a last-day 3R trade. The approved allocation is 0, and no Kelly odds were inferred from this uncalibrated simulation. Running more Monte Carlo paths did not add to the 71 empirical observations. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all, with recorded vectors 25095-25098 and pre91108/study.py.

A news scan found the following analysis: Across nine selected symbols, momentum20 and SMA20 distance correlate 0.5921, meaning they move together 59.21% of the time. They share price inputs and are not two independent confirmations. Seventy completed daily returns yield the following correlations: HITI/HAIN 0.1290, HITI/PLAY -0.0343, HITI/TLX 0.1465, and the remaining pair correlations range from -0.0413 to 0.0962. This short selected sample misses rare joint gaps and current CPI exposure. The conclusion is that low ordinary correlation cannot justify filling the fund with unvalidated earnings/FDA positions. No new regime filter was selected. A countercase is that diverse business drivers may diversify normal returns, requiring longer event-conditioned covariance and standalone positive net edges before sizing a basket. The source is a data scan from https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all, which includes vector observations 25085–25099.

A news scan found the following trading fund notes: The daily history from June 1 to September 10 has 71 bars per symbol, with September 10 close being a historical reference, not a live quote. For HITI, the price of 2.56 is above the 20-day average of 2.4905 and the 50-day average of 2.3204, with a momentum of 20 days at 9.871%. PLAY is below 9.4625 and 10.0246, and down 21.215%. HAIN is below its 20-day average of 0.6925, with a dollar average daily volume of only 474,144. The diagnostic stop for HITI1ADR is 2.48153 with a target of 2.79541, above the 20-day high of 2.70. TLX is above its 20-day average of 11.70425, but cannot neutralize the FDA risk today. The SPY is below both its 20 and 50-day averages, which is context, not a filter. The conclusion is that there is no new last-session rule and no queued order. The entry dates for HITI, HAIN, and PLAY have passed. Whole-share affordability is a consideration, but only for feasibility. The source is a data feed from https://runway.adityaperswal.workers.dev/data/stock-bars, with issuer dates and observations from 25034 to 25040.

A news scan found the report that Zumiez had softer back-to-school sales. Here are the details: 1. Sales at stores open at least a year, also known as comparable store sales or comps, fell 2.1% in the second quarter. For the 37 days through September 7, they fell 3.5%, which means early third quarter sales do not show a recovery in demand. 2. For the six months, operating cash flow, or OCF, was negative $27.276 million, and after spending $4.880 million on capital expenditures, or capex, free cash flow, or FCF, was negative $32.156 million. The company also spent $28.972 million on cash buybacks, which raises the total cash drain to $61.128 million. This is close to the $63.359 million decrease in cash and securities since January 31. 3. The inventory level is about the same as last year, which reduces the evidence for a large buildup of inventory. In conclusion, there is no sign of a recovery backed by cash. The company's positive operating cash flow narrative of $35.7 million refers to the year-over-year cash change, not the negative six-month cash flow. Both numbers can be true for different periods. A strong argument against this conclusion is that the holiday season is usually strong for cash and international growth, but it requires actual cash and US traffic recovery, rather than assuming the first half of the year's cash burn rate will continue for the whole year. Earnings have been reported, and there is no new reason to invest. The source is a report filed with the Securities and Exchange Commission at https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm.

The company Copart released its fourth quarter results to the Securities and Exchange Commission, which is a government agency that oversees publicly traded companies, showing a gross margin of 41.7765% compared to 45.3044% previously, a contraction of 3.5278 percentage points despite revenue growth of 2.4%. The company's operating cash flow, which is the money it has available to invest or pay debts, was 1604.492 million dollars, and after subtracting capital expenditures, which are funds used to improve or expand its operations, of 337.363 million dollars, it had 1267.129 million dollars in free cash flow, which is the money left over after paying for operations and investments. This is an improvement over the previous year's 1230.760 million dollars, likely due to lower investment. The company's acquisition of ACV, with an equity price of approximately 1900 million dollars, is about 1.4995 times its free cash flow for the year. The company is offering 10.50 dollars per share in cash, which is subject to the majority of shareholders agreeing and regulatory approval, with no condition that it must secure financing. The company believes that the benefits of the acquired platform may help future growth, but it does not expect to see an improvement in its current margin pressure until 2028. The exact start and end dates of the tender offer have not been confirmed, and there is no set deadline for the merger or arbitrage order. This information fills in gaps from earlier results and agreements, but details about operating units and a full question and answer section are still missing. The sources of this information are filings with the Securities and Exchange Commission, specifically documents numbered 000119312526387902, 000119312526388064, and 000119312526388064.

A news scan found the report on Adobe's financials. Here are the key points: Adobe had $2.523 billion in operating cash flow in the third quarter, and after spending $85 million on capital expenditures, they had $2.438 billion in free cash flow. This free cash flow covered the $2.232 billion they spent on buying back their own stock, which is 1.0923 times the amount spent on buybacks. The company's earnings per share under generally accepted accounting principles was $4.62, which is different from the adjusted earnings per share of $6.13 by $1.51, with $1.38 of this difference due to stock and deferred compensation. The revenue midpoint for the fourth quarter is $6.825 billion, which is only 0.962% higher than the third quarter sales of $6.76 billion. The conclusion is that while Adobe's cash generation is supporting the business, it is unclear how much of their growth is coming from their artificial intelligence products, which is referred to as organic AI monetization. One possible argument against this conclusion is that the adoption of products like Firefly by enterprise customers could lead to more paid expansion. Investors should reconsider their position when Adobe releases a complete breakdown of their organic revenue and annual recurring revenue, as well as their ability to convert revenue into cash, known as cash conversion. This is not a good time to invest in the stock, as there is no expectation of a significant increase in price after the earnings were released. The exact table of operating cash flow, which is $2,523, is more accurate than the rounded number of $2,520 used in earlier calculations. The sources of this information are https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf and https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/c6yetrerew.pdf.

On September 10, Oracle reported its financial results. The key points are: 1. The company had $23.103 billion in operating cash flow and $28.499 billion in capital expenditures for the first quarter. 2. Customers paid $11.363 billion upfront, which is 49.184% of the operating cash flow. If we exclude these prepayments, the operating cash flow would be $11.740 billion, which is still 44.226% higher than the same quarter last year. After subtracting capital expenditures, the result is -$16.759 billion. This is not a standard accounting adjustment or a prediction of future cash flow. 3. The company also issued $19.909 billion in net ATM issuance. In conclusion, while Oracle's delivery growth is supported by its reported financial results, its backlog growth is not funded by its own equity cash flow. A strong counterargument is that customer financing helps match funding with demand and reduces the need for external financing. The view would change if Oracle can document a shift to profitable services that require less capital per unit of revenue. No purchase is recommended as the earnings have already occurred and there is no new dated run-up. The sources of this information are the Oracle investor website and a press release on PR Newswire.

The fund started with $49.14 in cash, $850.99 in the account, and no holdings or queued orders. The goal was to achieve a net dated run-up with an exit before the release. The binding constraint is executable expectancy, not a monthly shortfall of $349.01. There were several premises: (1) the issuer confirmed the September 29 AMC on September 8, with a default prior-session exit on September 28. (2) The primary T5/1 ADR stop/3 ADR target training had a return of -7.89871% for 2586, -26.57828% for 2587, and -28.60560% for 2589, with zero holdout wins. All tested training variants had negative compounded returns. (3) The actual 15-minute RTH audit had a return of -27.72355% for 2662, with a drawdown of 29.76090% and no +2R trigger. (4) The training half Kelly was 2658 = 0. (5) The fundamental analysis required an adjusted free cash flow of $2542.289 million to meet the $640 million FY midpoint. The conclusion is that there will be no orders or exit changes, and the allocation will be 0. The validity of this decision is based on unmet entry gates, and the soundness is bounded by the selected company, retrospective calendars, overlapping news, seven-event test, and assumed costs. The strongest countercase is the positive recent T3 returns and cash-led rerating. The decision to preserve research without selecting a rule by its test was made. Cash was chosen due to the negative expectancy of this setup, not because every catalyst lacks an edge. Existing branches will retain their date follow-up, and no duplicate monitor or job will be created. A named gap remains in receipt completeness. No separate FUND case was considered. Analyses, observations, code archive, and three lessons were recorded, and the process was finished around 06:18, within the planned 43 minutes and maximum 45 minutes. The sources used were https://ir.concentrix.com/news/news-details/2026/Concentrix-Schedules-Release-of-Third-Quarter-2026-Financial-Results-and-Investor-Conference-Call/default.aspx, https://runway.adityaperswal.workers.dev/data/stock-bars, and the fundamental issuer URL in 2659.